Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Sponsor: Chengdu Kangnuoxing Biopharma,Inc.
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Official title: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-11-11
Completion Date
2028-05-08
Last Updated
2025-10-07
Healthy Volunteers
No
Conditions
Interventions
Stapokibart injection
subcutaneous injection
Placebo
subcutaneous injection
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China